Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 26, 2008. The report details a specific corporate action regarding the repurchase and cancellation of the company's ordinary shares, executed under authority granted by shareholders at the Annual General Meeting on May 21, 2008.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on share capital movements.
- Shares Purchased: 997,000 ordinary shares of 25 pence each.
- Purchase Date: August 26, 2008.
- Purchase Price: 1,254.0951 pence per share.
- Treasury Shares Held: 474,194,158 shares (representing 9.05% of total voting rights).
- Shares in Issue: 5,237,284,725 shares (excluding Treasury shares).
Material Changes
The primary material change is the reduction of the company's share capital through the cancellation of 997,000 repurchased shares. Consequently, the total number of shares in issue stands at 5,237,284,725, which serves as the denominator for shareholder notification calculations under the Financial Services Authority's Disclosure and Transparency Rules.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities.
Key Facts for Investor Verification
- Verify the total number of shares in issue (5,237,284,725) for accurate calculation of ownership percentages under disclosure rules.
- Confirm the updated Treasury share count (474,194,158) and its impact on total voting rights (9.05%).
- Note that the repurchase price of 1,254.0951 pence per share reflects the specific transaction on August 26, 2008, and may not represent the average cost of all treasury shares held.